Product information and disease descriptionProduct descriptionProduct informationPharmacology
Pharmacodynamics
9 evidence topics · 6 sources
Aqueous humor C1q target engagement: phase Ib glaucoma study
“Correspondingly, mean (SD) and median (min, max) unbound C1q at day 1 (preinjection) was 100.1 (99.9) and 51.6 (16, 254) ng/ml in sham, 110.0 (109.5) and 65.7 (23, 293) in the ANX007 2.5 mg dose group, and 110.0 (83.1) and 86.8 (14, 222) in the ANX007 5.0 mg dose groups.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Unbound C1q was reduced to undetectable levels at day 29 (< 0.6 ng/ml) in aqueous humor at both dose levels in all subjects” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Full engagement of C1q in the aqueous humor at day 29 in all treated subjects supports monthly or less-frequent dosing of ANX007 in future clinical studies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Serum C1q after intravitreal dosing: phase Ia glaucoma study
Dose selection for monthly intravitreal injection
In vitro binding and complement pathway selectivity
“The binding affinity of ANX007 to purified human C1q and to C1q captured from human and cynomolgus monkey serum were similar, with EC50 values of 136 pM (7.7 ng/mL), 147 pM (8 ng/mL), and 179 pM (9.5 ng/mL), respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“ANX007 specifically inhibited classical complement-mediated activation at 6 nM (300 ng/mL) and had no effect on the lectin or the alternative pathway” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Ocular target engagement in nonhuman primates
“In contrast, suppression of free-C1q levels was maintained at days 44 and 59 in all tissues except the optic nerve.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“C1q inhibition was near complete in all samples at day 44, approximately 2 weeks after the second dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These results demonstrate that aqueous humor C1q target engagement is reflected in C1q lowering in both vitreous and the retina.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Importantly, in clinical studies where vitreous and ocular tissues cannot be sampled, these data support the relevance of aqueous humor target engagement as a surrogate for retinal target engagement.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Preclinical pharmacology: photo-oxidative photoreceptor damage model
Preclinical pharmacology: intravitreal and systemic anti-C1q in a light damage model
“Genetic deletion or pharmacological inhibition of C1q provided protection against photoreceptor cell loss and preserved receptor cell function, even when inhibition was provided after damage had occurred” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Interestingly, while local (intravitreal) administration of an anti-C1q antibody was protective, systemic administration was not—presumably due to local production of C1q in the retina and to lower levels of antibody penetration into the eye with systemic dosing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote